2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.120 (Poster) Pre-diagnostic Serum Biomarkers With Prognostic Value for Lung Cancer

Pdf Summary

A study conducted at Vanderbilt University Medical Center in Nashville, TN, explored the use of pre-diagnostic serum biomarkers to enhance prognostic stratification in lung cancer patients. The study aimed to determine whether a biomarker panel could provide valuable prognostic information beyond clinical variables alone.<br /><br />The study collected serum samples and clinical information from 338 patients from 2003 to 2017. The patients were between the ages of 18 and 80 and had biopsy-confirmed malignancy diagnoses. The serum biomarkers measured included CA-125, CEA, HE4, ProGRP, CYFRA 21-1, NSE, CRP, SCC, and Ferritin. Clinical variables such as age, sex, smoking status, cancer history, and nodule location were also considered.<br /><br />The results showed that CA-125, NSE, HE4, ProGRP, CYFRA 21-1, and CRP biomarkers were significantly associated with recurrence-free survival, even after adjusting for tumor stage. A combined biomarker model including CA-125, CEA, HE4, ProGRP, CYFRA 21-1, NSE, and CRP, along with clinical variables, could successfully risk-stratify patients within staging groups.<br /><br />In particular, the biomarker-informed model was able to further differentiate between low, intermediate, and high-risk groups among stage I patients, potentially impacting post-resection chemotherapy decisions.<br /><br />However, it's important to note that the study had limitations, including a small sample size from only two centers, lack of external validation, and the use of overall survival as the primary outcome instead of cancer-specific or progression-free survival.<br /><br />The study suggests that a pre-treatment biomarker panel could be used to personalize lung cancer treatment plans based on the risk of future recurrence. The findings highlight the potential of biomarker panels to enhance prognostication beyond stage-based treatment stratification alone. The study was funded by the National Institutes of Health (NIH).

Asset Subtitle

Patrick Meyers

Keywords

Vanderbilt University Medical Center

pre-diagnostic serum biomarkers

prognostic stratification

lung cancer patients

biomarker panel

clinical variables

recurrence-free survival

combined biomarker model

risk-stratify patients

pre-treatment biomarker panel